NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial
Publication
, Conference
Mayo, MJ; Wigg, AJ; Roberts, SK; Arnold, H; Hassanein, TI; Leggett, BA; Bate, JP; Weltman, M; Carey, EJ; Muir, AJ; McCaughan, G; Bollipo, SJ ...
Published in: HEPATOLOGY
October 1, 2015
Duke Scholars
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2015
Volume
62
Start / End Page
263A / 264A
Location
San Francisco, CA
Publisher
WILEY-BLACKWELL
Conference Name
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Mayo, M. J., Wigg, A. J., Roberts, S. K., Arnold, H., Hassanein, T. I., Leggett, B. A., … Thompson, A. J. (2015). NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial. In HEPATOLOGY (Vol. 62, pp. 263A-264A). San Francisco, CA: WILEY-BLACKWELL.
Mayo, Marlyn J., Alan J. Wigg, Stuart K. Roberts, Hays Arnold, Tarek I. Hassanein, Barbara A. Leggett, John P. Bate, et al. “NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial.” In HEPATOLOGY, 62:263A-264A. WILEY-BLACKWELL, 2015.
Mayo MJ, Wigg AJ, Roberts SK, Arnold H, Hassanein TI, Leggett BA, et al. NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial. In: HEPATOLOGY. WILEY-BLACKWELL; 2015. p. 263A-264A.
Mayo, Marlyn J., et al. “NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial.” HEPATOLOGY, vol. 62, WILEY-BLACKWELL, 2015, pp. 263A-264A.
Mayo MJ, Wigg AJ, Roberts SK, Arnold H, Hassanein TI, Leggett BA, Bate JP, Weltman M, Carey EJ, Muir AJ, McCaughan G, Bollipo SJ, Gordon SC, Angus PW, Riordan S, Shiffman ML, Young E, Ling L, Luo J, Elliott M, Rossi S, DePaoli AM, Thompson AJ. NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial. HEPATOLOGY. WILEY-BLACKWELL; 2015. p. 263A-264A.
Published In
HEPATOLOGY
EISSN
1527-3350
ISSN
0270-9139
Publication Date
October 1, 2015
Volume
62
Start / End Page
263A / 264A
Location
San Francisco, CA
Publisher
WILEY-BLACKWELL
Conference Name
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics